Yu-Jun Cai Selected Research

salvicine

9/2008	Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H2O2 generation and topoisomerase II inhibition.
10/2005	Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yu-Jun Cai Research Topics

Disease

8	Neoplasms (Cancer) 07/2022 - 10/2005
6	Leukemia 04/2009 - 03/2004
3	Ataxia Telangiectasia (Louis Bar Syndrome) 08/2011 - 02/2007
3	Poisoning 09/2008 - 02/2007
2	Breast Neoplasms (Breast Cancer) 07/2022 - 10/2005
2	Carcinoma (Carcinomatosis) 11/2009 - 11/2007
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2024
1	Atrial Fibrillation 01/2022
1	Asthma (Bronchial Asthma) 01/2022
1	Hypertensive Crisis 01/2022
1	Sleep Apnea Syndromes (Sleep Apnea) 01/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2022
1	Bradycardia 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 08/2011
1	Mitochondrial Diseases (Mitochondrial Disease) 07/2008
1	Colonic Neoplasms (Colon Cancer) 06/2008
1	Hemolysis 12/2002

Drug/Important Bio-Agent (IBA)

5	DNA (Deoxyribonucleic Acid)IBA 11/2009 - 10/2005
3	trioctyl phosphine oxide (TOPO)IBA 09/2008 - 02/2007
2	PolyphenolsIBA 01/2012 - 08/2011
2	CurcuminIBA 01/2012 - 08/2011
2	Caffeine (No Doz)FDA LinkGeneric 08/2011 - 02/2007
2	amonafideIBA 11/2009 - 02/2007
2	ResveratrolIBA 04/2009 - 03/2004
2	AntioxidantsIBA 04/2009 - 12/2006
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2009 - 07/2008
2	Type II DNA Topoisomerases (Topoisomerase II)IBA 09/2008 - 02/2007
2	salvicineIBA 09/2008 - 10/2005
1	Liposomes (Liposome)IBA 07/2022
1	lonidamineIBA 07/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 07/2022
1	syrosingopineIBA 07/2022
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022
1	Etoposide (VP 16)FDA LinkGeneric 08/2011
1	Topoisomerase II InhibitorsIBA 08/2011
1	NaphthalimidesIBA 11/2009
1	IonsIBA 04/2009
1	DiterpenesIBA 09/2008
1	quinone (benzoquinone)IBA 09/2008
1	IronIBA 07/2008
1	artenimol (dihydroartemisinin)IBA 07/2008
1	CaspasesIBA 07/2008
1	p38 Mitogen-Activated Protein KinasesIBA 07/2008
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 06/2008
1	chimmitecanIBA 06/2008
1	14- ethyl- 2,5,11- trimethyl- 4,13,19,20- tetraoxa- tricyclo(14.2.1.1(7,10))eicosane- 3,12- dioneIBA 11/2007
1	AclarubicinIBA 02/2007
1	Phosphotransferases (Kinase)IBA 02/2007
1	gingerolIBA 11/2005
1	DiarylheptanoidsIBA 11/2005
1	Linoleic Acid (Linoleate)IBA 03/2004
1	EcdysteroidsIBA 12/2002
1	2,2'-azobis(2-amidinopropane) (ABAP)IBA 12/2002

Therapy/Procedure

2	Therapeutics 01/2024 - 09/2008
1	Immunotherapy 07/2022
1	Chemoprevention 04/2009